Apollo Biowellness, Inc. Re-Files Application with OTCMarkets.com
Apollo Biowellness (OTC Pink: KOAN) has announced the re-submission of its application to OTCMarkets.com to regain the ability to file disclosure reports on OTCIQ. The application is currently under review and pending approval from OTCMarkets.com.
Company President James W. Zimbler confirmed that once final approval is granted, the company will proceed with filing the necessary disclosure statements and financial information. Stakeholders can follow company updates on X (formerly Twitter) at @ApolloBioKOAN.
Apollo Biowellness (OTC Pink: KOAN) ha annunciato la nuova presentazione della sua domanda a OTCMarkets.com per riacquisire la possibilità di inviare rapporti di divulgazione su OTCIQ. La domanda è attualmente in fase di revisione e in attesa di approvazione da parte di OTCMarkets.com.
Il Presidente della società, James W. Zimbler, ha confermato che una volta ottenuta l'approvazione finale, l'azienda procederà con la presentazione delle dichiarazioni di divulgazione e delle informazioni finanziarie necessarie. Gli stakeholder possono seguire gli aggiornamenti dell'azienda su X (precedentemente Twitter) all'indirizzo @ApolloBioKOAN.
Apollo Biowellness (OTC Pink: KOAN) ha anunciado la re-presentación de su solicitud a OTCMarkets.com para recuperar la capacidad de presentar informes de divulgación en OTCIQ. La solicitud está actualmente en revisión y pendiente de aprobación por parte de OTCMarkets.com.
El presidente de la compañía, James W. Zimbler, confirmó que una vez otorgada la aprobación final, la empresa procederá a presentar las declaraciones de divulgación y la información financiera necesarias. Los interesados pueden seguir las actualizaciones de la empresa en X (anteriormente Twitter) en @ApolloBioKOAN.
Apollo Biowellness (OTC Pink: KOAN)은 OTCMarkets.com에 제출한 신청서를 재제출하여 OTCIQ에 공시 보고서를 제출할 수 있는 권한을 회복하려고 합니다. 현재 이 신청서는 검토 중이며 OTCMarkets.com의 승인을 기다리고 있습니다.
회사 사장 James W. Zimbler는 최종 승인이 내려지면 회사가 필요한 공시 서류와 재무 정보를 제출할 것이라고 확인했습니다. 이해관계자들은 X(구 트위터)에서 @ApolloBioKOAN을 통해 회사 소식을 팔로우할 수 있습니다.
Apollo Biowellness (OTC Pink : KOAN) a annoncé la nouvelle soumission de sa demande à OTCMarkets.com afin de retrouver la capacité de déposer des rapports de divulgation sur OTCIQ. La demande est actuellement en cours d'examen et en attente d'approbation par OTCMarkets.com.
Le président de l'entreprise, James W. Zimbler, a confirmé qu'une fois l'approbation finale accordée, la société procédera au dépôt des déclarations de divulgation et des informations financières nécessaires. Les parties prenantes peuvent suivre les mises à jour de l'entreprise sur X (anciennement Twitter) à @ApolloBioKOAN.
Apollo Biowellness (OTC Pink: KOAN) hat die erneute Einreichung seines Antrags bei OTCMarkets.com angekündigt, um die Möglichkeit zurückzuerlangen, Offenlegungsberichte über OTCIQ einzureichen. Der Antrag befindet sich derzeit in Prüfung und wartet auf die Genehmigung durch OTCMarkets.com.
Der Unternehmenspräsident James W. Zimbler bestätigte, dass das Unternehmen nach Erteilung der endgültigen Genehmigung mit der Einreichung der erforderlichen Offenlegungserklärungen und Finanzinformationen fortfahren wird. Interessierte können Unternehmensupdates auf X (ehemals Twitter) unter @ApolloBioKOAN verfolgen.
- None.
- Company currently unable to file disclosure reports on OTCIQ
- Pending regulatory approval from OTCMarkets.com for disclosure filings
- Lack of current financial information and disclosure statements available to investors
North Bergen, New Jersey--(Newsfile Corp. - July 3, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") announces that it submitted to OTCMarkets.com an application to be able to file disclosure reports on OTCIQ. The application process includes a review by OTCMarkets.com and is pending approval by OTCMarkets.com.
Evolutionary Biologics Ad Campaign
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/257594_63aba6f1c41abbbe_001full.jpg
James W. Zimbler, President, stated, "Our application to resume submitting disclosure statements and financial information has been submitted and we are awaiting final approval. As soon as final approval is granted, we will be filing the necessary statements."
You can follow and contact the Company on X at @ApolloBioKOAN.
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257594
FAQ
What did Apollo Biowellness (KOAN) announce regarding OTCMarkets.com on July 3, 2025?
When will Apollo Biowellness (KOAN) resume filing disclosure statements?
What is the current filing status of Apollo Biowellness (KOAN) on OTCMarkets?
How can investors follow Apollo Biowellness (KOAN) updates?
